Relmada Therapeutics, Inc. Appoints Gina Diguglielmo as Vice President and Head of Clinical Operations
April 03, 2019 at 08:00 am
Share
Relmada Therapeutics, Inc. announced that Gina DiGuglielmo has joined the company as vice president and head of clinical operations. Ms. DiGuglielmo previously served as clinical operations advisor of Relmada since June 2017. In her new role, Ms. DiGuglielmo will lead and oversee the clinical operations for Relmada's lead product candidate dextromethadone (REL-1017), a novel N-methyl-D-aspartate (NMDA) receptor antagonist in development as a rapid acting treatment of depression and potentially other CNS indications and will contribute to the advancement of the company's portfolio in the clinical phases. Ms. DiGuglielmo comes to Relmada with over 30 years of experience in clinical operations, both in pharmaceutical companies and contract research organizations.
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Companyâs lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
RELMADA THERAPEUTICS, INC. 
